Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Explore linked clinical trials.17 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer | Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Phase 3 | 2026-09-01 | NCT07797153 | |
| A Phase I Study of JSKN021 in Advanced Solid Tumors | Advanced Malignant Solid Tumors | Recruiting | Phase 1 | 2026-08-26 | NCT07617727 | |
| A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-04-16 | NCT07533123 | |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | Advanced Non-small Cell Lung Cancer | Recruiting | Phase 1 | 2026-03-30 | NCT06868732 | |
| JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Phase 2 | 2026-03-27 | NCT07497074 | |
| JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors | Advanced Solid Tumor Malignancies | Not yet recruiting | Phase 1 | 2026-03-16 | NCT07475559 | |
| A Study of JSKN027 in Patients With Advanced Solid Tumors | Advanced Malignant Solid Tumor | Not yet recruiting | Phase 1 | 2026-02-06 | NCT07391644 | |
| Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-02 | NCT05744427 | |
| JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-13 | NCT07336771 | |
| JSKN022 in Subjects With Advanced Malignant Solid Tumors | Advanced Malignant Solid Tumors | Recruiting | Phase 1 | 2025-12-23 | NCT07292402 | |
| A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-12-15 | NCT07283198 | |
| Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer | Inoperable Locally Advanced HER2-Negative Breast Cancer; Metastatic HER2-Negative Breast Cancer | Recruiting | Phase 1 / Phase 2 | 2025-09-17 | NCT06942234 | |
| JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2025-09-12 | NCT06079983 | |
| Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | Advanced Non-small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2025-01-15 | NCT06775483 | |
| JSKN033 in Chinese Subjects with Advanced Malignant Tumors | Advanced Malignant Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2025-01-13 | NCT06770881 | |
| JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 3 | 2024-12-31 | NCT06751485 | |
| To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors | Advanced Malignant Solid Tumor | Recruiting | Phase 1 | 2024-09-19 | NCT06592417 |